Report Overview

The Osteoarthritis drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Rheumatic diseases have not received much focus in African Countries owing to the overwhelming prevalence of infectious diseases. With improved health outcomes for infectious diseases, increase in life expectancy and better health policies, chronic diseases like osteoarthritis are receiving attention. In Kenya, knee, hip and hand Osteoarthritis prevalence is 15%, 3% and 5% respectively. In a study done in Kenya, 51%, 21% and 59.5% of osteoarthritis patients were found to have hypertension, diabetes and overweight or obese, respectively.



Market Drivers

The market is primarily driven by the rising prevalence of osteoarthritis in Kenyan population. The prevalence of osteoarthritis is found to be higher in females than males. Lack of education, low socioeconomic status, limited access to health care and some religious and cultural beliefs also contribute to a reluctance or delay in seeking medical care.

The Osteoarthritis market is anticipated to grow in the forecast period owing to driving factors such as increasing lifestyle changes, growing number of obesity cases, rise in geriatric population, high awareness among the people, advancements in terms of technology and government reimbursement policies.

Presence of strong pipelines drugs for osteoarthritis treatment is one of the crucial reasons for growth in osteoarthritis drug market in Kenya.

However, Lack of trained human resources for proper diagnosis and treatment of the disease in Kenya is one of the factors responsible of restricting growth of the market.

Chronic use of NSAIDs leads to development of chronic kidney disease (CKD) and other side effects. Side effects of the drugs coupled with lack of awareness and human resources for diagnosis and treatment are restricting growth of osteoarthritis drug market.